← Every company
Veracyte Inc Patents
What Veracyte Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
VCYT on carbonthat →Filings on file
20
Granted
2
Still pending
18
Filed under
3 names
20 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| BIOMARKERS IN PRE-OPERATIVE PROSTATE CANCERFiled as VERACYTE, INC.2026-02-05ELAI DAVICIONI | pending |
| METHODS AND SYSTEMS OF CLASSIFYING TUMOR TISSUE SAMPLESG16H 50/20, C12Q 1/6886, G16H 40/67, G16H 10/40, G16H 15/00, G16H 50/30, G16H 50/70, G06N 20/20, G06N 20/00, G16B 25/10, G16B 40/00, G16B 20/00, G01N 33/5759, G01N 33/57557, C12Q2600/112, C12Q2600/118, C12Q2600/158, G01N 33/5091, G01N2800/56Filed as Veracyte, Inc.2025-12-15Yangyang Hao | pending |
| METHODS FOR TREATMENT OF THYROID CANCERG16B 25/10, C12Q 1/6886, Y02A 90/10, G16H 10/40, G16H 15/00, G16H 50/30, G16H 50/20, G16H 20/00, G16H 40/63, G06N 20/00, G16Z 99/00, G16B 40/00, G16B 25/00, G16B 40/20, G01N 33/57557, C12Q 1/6883, C12Q2600/112, C12Q2600/156, C12Q2600/158, G01N 33/5091Filed as Veracyte, Inc.2025-11-21Giulia C. Kennedy | pending |
| PROGNOSIS AND TREATMENT OF METASTATIC PROSTATE CANCERFiled as VERACYTE, INC.2025-08-25YANG LIU | pending |
| METHODS FOR TUMOR FRACTION ANALYSIS USING SPECTRAL ANALYSIS METHODSFiled as VERACYTE, INC.2025-06-30DANIELLE AFTERMAN | pending |
| METHODS AND SYSTEMS FOR ESTIMATION OF MOLECULAR RESIDUAL DISEASE, TUMOR MUTATIONAL BURDEN, AND CLONAL HEMATOPOIESISFiled as VERACYTE, INC.2025-05-30FRANCES ARMSTRONG | pending |
| METHODS FOR CLASSIFICATION OF TISSUE SAMPLES AS POSITIVE OR NEGATIVE FOR CANCERC12Q 1/6883, C12Q 1/6886, C12Q2600/112, C12Q2600/156, C12Q2600/158Filed as Veracyte, Inc.2025-05-02Giulia C. Kennedy | pending |
| SYSTEMS AND METHODS OF DIAGNOSING IDIOPATHIC PULMONARY FIBROSISC12Q 1/686, C12Q 1/6883, C12Q 1/6806, C12Q 1/6874, C12Q 1/6876, C12Q 1/6886, C12Q2600/112, C12Q2600/156, C12Q2600/158Filed as Veracyte, Inc.2025-04-30Giulia C. Kennedy | pending |
| METHODS FOR TREATMENT OF THYROID CANCERG16B 25/10, G16H 10/40, G16H 15/00, G16H 50/30, G16H 50/20, G16H 20/00, G16H 40/63, G06N 20/00, G16Z 99/00, G16B 40/00, G16B 25/00, G16B 40/20, G01N 33/57557, C12Q 1/6883, C12Q 1/6886, C12Q2600/112, C12Q2600/156, C12Q2600/158, G01N 33/5091Filed as Veracyte, Inc.2025-04-17Giulia C. Kennedy | pending |
| BIOMARKERS IN PRE-OPERATIVE PROSTATE CANCERFiled as Veracyte, Inc.2025-02-07Elai Davicioni | pending |
| PROGNOSIS AND TREATMENT OF MOLECULAR SUBTYPES OF PROSTATE CANCERG16B 25/10, C12Q 1/6886, G16H 20/40, G16H 10/60, G16H 50/20, G16H 20/10, G16B 40/20, G01N 33/57555, A61K 31/337, A61K 31/395, A61K 31/69, A61K 38/07, A61K 45/06, A61K2300/00, A61N 5/10, C12Q2600/118, C12Q2600/158, G01N2800/52Filed as Veracyte, Inc.2024-11-11Elai Davicioni | pending |
| METHODS FOR TREATMENT OF THYROID CANCERG16B 25/10, C12Q 1/6886, Y02A 90/10, G16H 10/40, G16H 15/00, G16H 50/30, G16H 50/20, G16H 20/00, G16H 40/63, G06N 20/00, G16Z 99/00, G16B 40/00, G16B 25/00, G16B 40/20, G01N 33/57557, C12Q 1/6883, C12Q2600/112, C12Q2600/156, C12Q2600/158, G01N 33/5091Filed as Veracyte, Inc.2024-09-23Giulia C. Kennedy | 12305238 |
| METHODS FOR PREDICTING RESPONSE TO AN IMMUNOTHERAPEUTIC TREATMENT IN A PATIENT WITH A CANCERG01N 33/57492, G01N 33/57419, G01N 33/6872, G01N2333/70517, G01N2333/70596, G01N2800/52Filed as VERACYTE SAS2024-09-17ALBOUKADEL KASSAMBARA | pending |
| GENETIC SIGNATURES TO PREDICT PROSTATE CANCER METASTASIS AND IDENTIFY TUMOR AGGRESSIVENESSC12Q 1/6886, C12Q2600/112, C12Q2600/118, C12Q2600/158, G01N 33/57434, G01N2800/52Filed as Veracyte, Inc.2024-09-04Elai Davicioni | pending |
| METHODS FOR CLASSIFICATION OF TISSUE SAMPLES AS POSITIVE OR NEGATIVE FOR CANCERC12Q 1/6883, C12Q 1/6886, C12Q2600/112, C12Q2600/156, C12Q2600/158Filed as Veracyte, Inc.2024-09-03Giulia C. Kennedy | 12297503 |
| METHODS AND COMPOSITIONS FOR CLASSIFICATION OF SAMPLESG16H 50/20, C12Q 1/6886, Y02A 90/10, G16H 10/40, G16B 25/10, G16B 40/00, G16B 40/30, G16B 25/00, G16B 40/20, G01N 33/57505, G01N 33/57585, G01N 33/57557, C12Q2600/112, C12Q2600/158Filed as Veracyte, Inc.2024-08-05Jonathan I. Wilde | pending |
| METHODS FOR TUMOR FRACTION ANALYSIS USING SPECTRAL COPY NUMBER VARIANT PROCESSINGFiled as Veracyte, Inc.2024-07-01Danielle Afterman | pending |
| METHODS AND SYSTEMS OF CLASSIFYING TUMOR TISSUE SAMPLESFiled as VERACYTE, INC.2024-05-31YANGYANG HAO | pending |
| METHODS AND SYSTEMS FOR ESTIMATION OF MOLECULAR RESIDUAL DISEASE, TUMOR MUTATIONAL BURDEN, AND CLONAL HEMATOPOIESISFiled as Veracyte, Inc.2024-05-31Danielle Afterman | pending |
| USE OF A GENETIC SIGNATURE DIAGNOSTICALLY TO EVALUATE TREATMENT STRATEGIES FOR PROSTATE CANCERC12Q 1/6886, C12Q2600/106, C12Q2600/118, C12Q2600/156, C12Q2600/158, C40B 30/04, C40B 40/06, G01N 33/57434, G01N2800/52Filed as Veracyte, Inc.2024-02-20Hussam Al-Deen Ashab | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on VCYT
Company overviewEverything on VCYT in one place, with the price.SEC filingsWhat VCYT's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat VCYT's own officers and directors buy and sell.Planned salesSales VCYT insiders have filed notice of.Executive payWhat VCYT awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in VCYT.Funds holding itWhich funds and ETFs hold VCYT, and how big a bet.Federal contractsWhat federal agencies pay VCYT.